Skip to main content

Table 3 Virologic Outcomes of EI-AED Compared to Non-AED Subjects

From: Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study

  EI-AED
(N = 19)
Non-AED
(N = 190)
OR (95% CI) or
Difference ± SE
Adjusted for VL at
HAART Initiation
OR (95% CI) or
Difference ± SE
First HAART/AED Overlap     
   Virologic failure 10/16 (62.5%) 62/146 (42.5%) 2.26 (0.78 - 6.54)
P = 0.134
4.30 (1.02 - 18.07)
P = 0.046
   Average VL during period (log10) 3.3 ± 1.3 (n = 19) 2.9 ± 1.2 (n = 184) 0.4 ± 0.3;
P = 0.198
0.3 ± 0.3;
P = 0.195
   VL <400 at 6 months 4/12 (33.3%) 89/160 (55.6%) 0.40 (0.12 - 1.38)
P = 0.146
0.30 (0.06 - 1.48)
P = 0.139
   VL <400 at 12 months 4/11 (36.4%) 80/125 (64.0%) 0.32 (0.09 - 1.16)
P = 0.083
0.17 (0.03 - 0.89)
P = 0.036
  1. OR (odds ratio): Odds of virologic event for EI-AED cases versus odds for non-AED controls; VL, viral load (copies/mL)